Federal grants to Coridea, LLC
Coridea, LLC in Teaneck, New York received $10.6 million in federal grants from fiscal 2021 to 2025, across 8 awards. Its largest program was Cardiovascular Diseases Research, with $4.9 million. In fiscal 2025 it was awarded $3.7 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$10.6 million
- Awards8
- Awarded in FY 2025$3.7 million
- Largest award$2.7 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 3 | $1.9 million |
| FY 2022 | 3 | $1.8 million |
| FY 2023 | 2 | $1.8 million |
| FY 2024 | 2 | $1.3 million |
| FY 2025 | 2 | $3.7 million |
Programs that fund Coridea, LLC
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 3 | $4.9 million |
| Drug Use and Addiction Research Programs | 3 | $3.9 million |
| Cancer Treatment Research | 1 | $1.6 million |
| Biomedical Research and Research Training | 1 | $274,839 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 8 | $10.6 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Transcutaneous phrenic nerve stimulation for treating opioid overdose - project summary. This UG3/UH3 project is focused on the development of an automated external respiratory support (AERS) system intended to rescue people from opioid-induced respiratory depression (OIRD). Aers is a portable elect | Drug Use and Addiction Research Programs | September 15, 2025 | $2.7 million |
| Minimally invasive high intensity therapeutic ultrasound for the treatment of obstructive hypertrophic cardiomyopathy - project summary obstructive hypertrophic cardiomyopathy (OHCM) is a common inherited heart disease that can cause major limitations to daily acts of living, poor prognosis, and mor | Cardiovascular Diseases Research | April 30, 2023 | $2.0 million |
| Endobronchial supervalve for the treatment of emphysema | Cardiovascular Diseases Research | November 24, 2020 | $1.9 million |
| Novel minimally invasive endobronchial approach for lung cancer ablation - project summary: lung cancer is one of the most aggressive and common malignancies world-wide. While surgical resection remains the best chance of cure, only 20% of patients are eligible for surgery. The remaining patients ar | Cancer Treatment Research | September 24, 2021 | $1.6 million |
| Ent-based approach to cervical phrenic nerve stimulation for the treatment of central sleep apnea - project summary central sleep apnea (CSA) is a disorder where patients intermittently lose the drive to breath, though they have with no peripheral nerve disorder nor do they have any airway abnormali | Cardiovascular Diseases Research | September 11, 2025 | $982,086 |
| Transcutaneous phrenic nerve stimulation for treating opioid overdose - in the U.S., an exponential increase in opioid-related overdose deaths has occurred over the last decade. The hallmark symptom of an opioid-related overdose is decreased respiration, which can result in permanent hypoxic brain i | Drug Use and Addiction Research Programs | September 1, 2023 | $927,319 |
| Coridea NIH i-corps program - project summary: opioid use disorder (OUD) stands out as being the most lethal of addictions. Not only is there a significant risk of overdose, the life span of a patient with oud decreased by almost 20 years. Furthermore, oud is frequently comorbid with other disorders | Drug Use and Addiction Research Programs | September 22, 2021 | $278,784 |
| Stellate ganglion stimulation in septic shock to improve hemodynamics and vasopressor requirements - project summary: sepsis is one of the leading sources of morbidity and mortality in the us, impacting nearly 1.7 million adults each year and upwards of 250,000 deaths annually. Septic shock is sepsi | Biomedical Research and Research Training | June 5, 2024 | $274,839 |
Questions people ask
How much federal grant money does Coridea, LLC get?
$10.6 million in 8 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Coridea, LLC the most?
The Department of Health and Human Services, with $10.6 million in 8 awards.
What is Coridea, LLC's largest federal grant?
$2.7 million under Drug Use and Addiction Research Programs, with its first action in the period on September 15, 2025. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Coridea, LLC?
Its largest are Cardiovascular Diseases Research, Drug Use and Addiction Research Programs and Cancer Treatment Research.
Largest federal grant recipients in New York · Federal grants in New York